Press Releases

Date Title    
Toggle Summary Editas Medicine Reports Data Demonstrating the Potential of CRISPR/Cas9 to Enable Gene Repair Through a New Mechanism
Toggle Summary Editas Medicine Reports New Data Characterizing Novel Properties of Staphylococcus aureus Cas9 as a Tool for CRISPR-Based Genome Engineering
Toggle Summary Editas Medicine Licenses Genome Editing Technology from Broad Institute and Harvard University
Toggle Summary Editas Medicine Licenses Genome Editing Technology from Duke University
Toggle Summary Editas Medicine Licenses Genome Editing Technology from Massachusetts General Hospital
Toggle Summary FierceBiotech names Editas Medicine as one of its “Fierce 15” Biotech Companies of 2014
Toggle Summary Editas Medicine Appoints Katrine S. Bosley to Chief Executive Officer
Toggle Summary Editas Medicine Selected for Hottest Healthcare Startup at the New England Venture Capital Association’s 2014 NEVY Awards
Toggle Summary Editas Medicine Co-founders Present Novel Methods for Improving Genome Editing Specificity in Two Nature Biotechnology Papers
Toggle Summary Broad Institute awarded first patent for engineered CRISPR-Cas9 system
Toggle Summary Broad, MIT researchers reveal structure of key CRISPR complex
Toggle Summary Editas Medicine Co-founder Publishes High-Resolution Structures of MajorCas9 Enzymes in Science
Toggle Summary Editas Medicine Co-founder Develops Novel Approach to Increase Specificity of CRISPR/Cas9 Technology; Findings Published in Nature Biotechnology
Toggle Summary Editas Medicine Created to Discover and Develop Novel Class of Genome Editing Therapeutics